ProCE Banner Activity

CE / CME

Small Cell Lung Cancer: Applying the Latest Developments in Community Practice

Multimedia

Watch this on-demand webcast with expert insights on best practices for community management of extensive-stage small cell lung cancer, including treatment selection in the newly diagnosed and relapsed settings, managing treatment-related adverse events, and important clinical trials.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour

Released: September 15, 2022

Expiration: September 14, 2023

No longer available for credit.

Share

Faculty

Christine L. Hann

Christine L. Hann, MD, PhD

Associate Professor of Oncology
Director, Small Cell Lung Cancer Therapeutics
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

G1 Therapeutics Inc

Ipsen Biopharmaceuticals Inc

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare professionals who treat and manage patients with small-cell lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate into practice the results of clinical trials demonstrating improved outcomes for patients with ES-SCLC using immune checkpoint inhibitor–based combinations
  • Delineate the dose, schedule of administration, and dose adjustments for each of the immune checkpoint inhibitor and etoposide/platinum combinations currently indicated for ES-SCLC
  • Plan therapeutic strategies for patients with metastatic SCLC and disease progression on or after platinum-based chemotherapy
  • Manage immune-related adverse events using available clinical data, guidelines, and online clinical resources and tools
  • Identify patients with SCLC who are appropriate for enrollment on ongoing clinical trials

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Christine L. Hann, MD, PhD

Associate Professor of Oncology
Director, Small Cell Lung Cancer Therapeutics
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Christine L. Hann, MD, PhD: consultant/advisor/speaker: Amgen, AstraZeneca, Janssen; researcher: AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech.

Staff Disclosure

Staff

Kelly Brandt, PharmD

Kelly Brandt, PharmD, has no relevant financial relationships to disclose.

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant financial relationships to disclose.

Kayla Douglas, PharmD

Director of Pharmacy
Mississippi Center for Advanced Medicine
Madison, Mississippi

Kristi Kay Orbaugh, MSN, NP, AOCNP: consultant/advisor/speaker: AstraZeneca, Bristol-Myers Squibb, DSI, Gilead Sciences, Lilly, Morphosys, Pfizer, Regeneron, Sanofi.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant financial relationships to disclose.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant financial relationships to disclose.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant financial relationships to disclose.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant financial relationships to disclose.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-224-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 15, 2022, through September 14, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this activity is to improve the knowledge and competence of learners to integrate currently available and emerging therapies for treatment of SCLC.